Comprehensive genomic profiling turns a single tumor sample into a document that multiple specialists can act on, and clear reporting standards make that document trustworthy. The 106-gene solid tumor panel is built for broad somatic coverage and for producing a medication-oriented report. Its value depends as much on documentation discipline as on sequencing depth.
Hybrid-capture sequencing covers 106 genes across point mutations, copy-number changes, and rearrangements from one extract. Variants are classified by established frameworks into tiers of therapeutic significance, and each is linked to approved or investigational medications. The structured report separates confirmed findings from variants of uncertain significance so prescribers are not misled.
The panel serves patients with advanced solid tumors lacking a single dominant driver, or those being considered for clinical trials and matched therapy. It is also used when a broad profile is needed to exhaust actionable possibilities. The output supports tumor-board discussion across disease sites.
FFPE tissue or a validated liquid biopsy is accepted, and the report includes gene list, variant table, tier assignments, and a medication summary. Turnaround is roughly 10–14 working days given the larger panel. Reports follow a consistent template suitable for inclusion in the medical record.
Extracts are frozen and shipped on dry ice; FFPE scrolls travel with desiccant. For hospital networks, standardized requisitions and audit-ready reports ease compliance review. Give Life Time International maintains version-controlled report formats so each result meets documentation expectations. A dedicated requisition that captures prior therapy and the specimen index date helps the laboratory return a report aligned with the patient's current medication context, reducing back-and-forth between the clinic and the testing team. Periodic report-format reviews keep the document consistent as guidelines evolve, which protects its value as a long-term reference in the medical record.
Q: How are variants classified in the 106-gene report? Findings are tiered by therapeutic significance using recognized frameworks, separating actionable variants from those of uncertain meaning.
Q: Is the report suitable for clinical-trial matching? Yes. The broad gene coverage and structured output make it useful for identifying trial-eligible molecular profiles.
Q: What documentation supports audit and reimbursement? Each report carries the gene list, assay version, and tier assignments in a consistent template that satisfies record-keeping needs.
Q: Can liquid biopsy substitute for tissue on this panel? A validated liquid biopsy is accepted when tissue is insufficient, though tissue generally provides broader coverage.
Comprehensive genomic profiling turns a single tumor sample into a document that multiple specialists can act on, and clear reporting standards make that document trustworthy. The 106-gene solid tumor panel is built for broad somatic coverage and for producing a medication-oriented report. Its value depends as much on documentation discipline as on sequencing depth.
Hybrid-capture sequencing covers 106 genes across point mutations, copy-number changes, and rearrangements from one extract. Variants are classified by established frameworks into tiers of therapeutic significance, and each is linked to approved or investigational medications. The structured report separates confirmed findings from variants of uncertain significance so prescribers are not misled.
The panel serves patients with advanced solid tumors lacking a single dominant driver, or those being considered for clinical trials and matched therapy. It is also used when a broad profile is needed to exhaust actionable possibilities. The output supports tumor-board discussion across disease sites.
FFPE tissue or a validated liquid biopsy is accepted, and the report includes gene list, variant table, tier assignments, and a medication summary. Turnaround is roughly 10–14 working days given the larger panel. Reports follow a consistent template suitable for inclusion in the medical record.
Extracts are frozen and shipped on dry ice; FFPE scrolls travel with desiccant. For hospital networks, standardized requisitions and audit-ready reports ease compliance review. Give Life Time International maintains version-controlled report formats so each result meets documentation expectations. A dedicated requisition that captures prior therapy and the specimen index date helps the laboratory return a report aligned with the patient's current medication context, reducing back-and-forth between the clinic and the testing team. Periodic report-format reviews keep the document consistent as guidelines evolve, which protects its value as a long-term reference in the medical record.
Q: How are variants classified in the 106-gene report? Findings are tiered by therapeutic significance using recognized frameworks, separating actionable variants from those of uncertain meaning.
Q: Is the report suitable for clinical-trial matching? Yes. The broad gene coverage and structured output make it useful for identifying trial-eligible molecular profiles.
Q: What documentation supports audit and reimbursement? Each report carries the gene list, assay version, and tier assignments in a consistent template that satisfies record-keeping needs.
Q: Can liquid biopsy substitute for tissue on this panel? A validated liquid biopsy is accepted when tissue is insufficient, though tissue generally provides broader coverage.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
